NCT02572583

A Clinical Study of Treating Influenza With Liugan Shuangjie Heji

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Dongfang Hospital Beijing University of Chinese Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This prospective randomized controlled trial studies the efficacy and safety of treating influenza with the reconciling exterior and interior therapy. A total of 300 cases of seasonal flu in Beijing is to be collected, and divided into one treatment group and two control groups. Patients in the treatment group will receive Liugan Shuangjie Heji, while patients in control groups will receive Shufeng Jiedu Capsule and Oseltamivir Phosphate Capsule respectively, for a course of 5 days. The study assesses the efficacy and safety of treating influenza with the reconciling therapy based on the following outcome measures: the time it takes from the medicine intake to 0.5℃ drop of body temperature, and the time it takes for the body temperature to return to normal.

Conditions

• Influenza

Interventions

Type	Name	Description
DRUG	Liugan Shuangjie Heji
DRUG	Shufeng Jiedu Capsule
DRUG	Oseltamivir Phosphate Capsule

Timeline

• Start date: 2014-11-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2015-10-09
• Last updated: 2015-10-09

Locations

1 site across 1 country: China